Literature DB >> 12701333

The orphan drug backlash.

Thomas Maeder.   

Abstract

Mesh:

Year:  2003        PMID: 12701333     DOI: 10.1038/scientificamerican0503-80

Source DB:  PubMed          Journal:  Sci Am        ISSN: 0036-8733            Impact factor:   2.142


× No keyword cloud information.
  5 in total

1.  Biosimilar growth hormone.

Authors:  Paul Saenger
Journal:  Indian J Pediatr       Date:  2011-11-23       Impact factor: 1.967

2.  Growth hormone and health policy.

Authors:  Leona Cuttler; J B Silvers
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

3.  Adopting an orphan.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

4.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

5.  Pricing and reimbursement of orphan drugs: the need for more transparency.

Authors:  Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.